A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Rising Dose Study to Evaluate the Safety, Tolerability and Pharmcokinetics of Escalating Single or Multiple Subcutaneous Doses of TAK-094 in Healthy Lean and Overweight/Obese Otherwise Healthy Subjects

Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Rising Dose Study to Evaluate the Safety, Tolerability and Pharmcokinetics of Escalating Single or Multiple Subcutaneous Doses of TAK-094 in Healthy Lean and Overweight/Obese Otherwise Healthy Subjects

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs TAK 094 (Primary)
  • Indications Diabetes mellitus; Obesity
  • Focus Adverse reactions; First in man
  • Sponsors Takeda Europe Research & Development Centre
  • Most Recent Events

    • 06 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top